+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Production of Tumor Necrosis Factor-Alpha in Patients on Hemodiafiltration

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The systemic production of tumor necrosis factor (TNF)-α was evaluated in uremic patients before and after hemodiafiltration (HDF) and paired filtration dialysis (PFD) and in the interdialytic period. Both HDF and PFD were performed using polysulfone dialyzers with either standard or ultrapure dialysis fluid. TNF-α was quantitated by using a specific biological assay based on its cytotoxic effect on a TNF-sensitive human melanoma cell line SK-MEL-109. Postdialytic mean plasma TNF-α levels decreased, albeit not significantly, in regard to predialytic values. These results differ from those obtained in patients on HDF using other high-permeability membranes such as polymethylmethacrylate and polyacrylonitrile (AN 69) as recently described by us. Of interest, the adoption of ultrapure dialysis fluid resulted in a marked reduction in the interdialytic production of TNF-α. These results suggest that the enhanced production of TNF-α in patients dialyzed with high-permeability membranes is mainly dependent upon the bacteriological purity of dialysis fluid.

          Related collections

          Author and article information

          S. Karger AG
          11 December 2008
          : 61
          : 2
          : 135-138
          aBellco Laboratories, Mirandola, Modena; bServizio di Nefrologia e Dialisi, Ospedale di Ciriè, Torino; cLaboratorio di Immunopatologia, Cattedra di Nefrologia, Università di Torino; dCattedra di Nefrologia Sperimentale, 2 a Facoltà di Medicina, Università di Napoli, Italy
          186860 Nephron 1992;61:135–138
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Original Paper

          Cardiovascular Medicine, Nephrology

          Hemodiafiltration, TNF-α, Biocompatibility


          Comment on this article